2nd Circ. Upholds Merck Win In Bellwether Fosamax Trial

Law360, New York (January 31, 2013, 4:56 PM EST) -- The Second Circuit denied a plaintiff's bid for a retrial Wednesday in a bellwether case in multidistrict litigation claiming Merck & Co.'s bone drug Fosamax causes jaw deterioration, ruling a lower court did not err when it discredited expert testimony.

A three-judge panel issued an opinion upholding a New York federal judge's decision to grant summary judgment to Merck on plaintiff Linda Secrest's claim that the drugmaker failed to warn of the risks of Fosamax use.

In a separate summary order, it ruled that the judge's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.